Use of postmenopausal hormone therapy and risk of Alzheimer's disease in Finland: nationwide case-control study
- PMID: 30842086
- PMCID: PMC6402043
- DOI: 10.1136/bmj.l665
Use of postmenopausal hormone therapy and risk of Alzheimer's disease in Finland: nationwide case-control study
Abstract
Objectives: To compare the use of hormone therapy between Finnish postmenopausal women with and without a diagnosis for Alzheimer's disease.
Design: Nationwide case-control study.
Setting: Finnish national population and drug register, between 1999 and 2013.
Participants: All postmenopausal women (n=84 739) in Finland who, between 1999 and 2013, received a diagnosis of Alzheimer's disease from a neurologist or geriatrician, and who were identified from a national drug register. Control women without a diagnosis (n=84 739), matched by age and hospital district, were traced from the Finnish national population register.
Interventions: Data on hormone therapy use were obtained from the Finnish national drug reimbursement register.
Main outcome measures: Odds ratios and 95% confidence intervals for Alzheimer's disease, calculated with conditional logistic regression analysis.
Results: In 83 688 (98.8%) women, a diagnosis for Alzheimer's disease was made at the age of 60 years or older, and 47 239 (55.7%) women had been over 80 years of age at diagnosis. Use of systemic hormone therapy was associated with a 9-17% increased risk of Alzheimer's disease. The risk of the disease did not differ significantly between users of estradiol only (odds ratio 1.09, 95% confidence interval 1.05 to 1.14) and those of oestrogen-progestogen (1.17, 1.13 to 1.21). The risk increases in users of oestrogen-progestogen therapy were not related to different progestogens (norethisterone acetate, medroxyprogesterone acetate, or other progestogens); but in women younger than 60 at hormone therapy initiation, these risk increases were associated with hormone therapy exposure over 10 years. Furthermore, the age at initiation of systemic hormone therapy was not a decisive determinant for the increase in risk of Alzheimer's disease. The exclusive use of vaginal estradiol did not affect the risk of the disease (0.99, 0.96 to 1.01).
Conclusions: Long term use of systemic hormone therapy might be accompanied with an overall increased risk of Alzheimer's disease, which is not related to the type of progestogen or the age at initiation of systemic hormone therapy. By contrast, use of vaginal estradiol shows no such risk. Even though the absolute risk increase for Alzheimer's disease is small, our data should be implemented into information for present and future users of hormone therapy.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Conflict of interest statement
Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: support from Helsinki University Hospital and the Jane and Aatos Erkko Foundation for the submitted work; speaker and consulting fees for Mylan (HS-P, TSM) and Astellas (TSM); funding for congress trips from Merck, Sharp, and Dohme (HS-P), Astellas (PR-S), and Olympus (PR-S); FH and PV work for EPID Research, which performs financially supported studies for several pharmaceutical companies; no other relationships or activities that could appear to have influenced the submitted work.
Figures
![Fig 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6402043/bin/savh045930.f1.gif)
![Fig 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6402043/bin/savh045930.f2.gif)
Comment in
-
Menopausal hormone therapy and cognition.BMJ. 2019 Mar 6;364:l877. doi: 10.1136/bmj.l877. BMJ. 2019. PMID: 30842090 No abstract available.
Similar articles
-
Risk of Alzheimer's disease among users of postmenopausal hormone therapy: A nationwide case-control study.Maturitas. 2017 Apr;98:7-13. doi: 10.1016/j.maturitas.2017.01.002. Epub 2017 Jan 9. Maturitas. 2017. PMID: 28274328
-
Breast cancer risk in postmenopausal women using estradiol-progestogen therapy.Obstet Gynecol. 2009 Jan;113(1):65-73. doi: 10.1097/AOG.0b013e31818e8cd6. Obstet Gynecol. 2009. PMID: 19104361
-
Postmenopausal hormone therapy is accompanied by elevated risk for uterine prolapse.Menopause. 2019 Feb;26(2):140-144. doi: 10.1097/GME.0000000000001173. Menopause. 2019. PMID: 29994974
-
Estrogen-containing hormone therapy and Alzheimer's disease risk: understanding discrepant inferences from observational and experimental research.Neuroscience. 2006;138(3):1031-9. doi: 10.1016/j.neuroscience.2005.06.017. Epub 2005 Nov 28. Neuroscience. 2006. PMID: 16310963 Review.
-
Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003.Climacteric. 2003 May;6 Suppl 1:11-36. Climacteric. 2003. PMID: 12945798 Review.
Cited by
-
Risks and benefits of hormone therapy after menopause for cognitive decline and dementia: A conceptual review.Maturitas. 2024 Jun;184:108003. doi: 10.1016/j.maturitas.2024.108003. Epub 2024 Apr 17. Maturitas. 2024. PMID: 38649310 Review.
-
Estradiol enhanced neuronal plasticity and ameliorated astrogliosis in human iPSC-derived neural models.Regen Ther. 2024 Jan 12;25:250-263. doi: 10.1016/j.reth.2023.12.018. eCollection 2024 Mar. Regen Ther. 2024. PMID: 38293585 Free PMC article.
-
Systematic review and meta-analysis of the effects of menopause hormone therapy on risk of Alzheimer's disease and dementia.Front Aging Neurosci. 2023 Oct 23;15:1260427. doi: 10.3389/fnagi.2023.1260427. eCollection 2023. Front Aging Neurosci. 2023. PMID: 37937120 Free PMC article.
-
Copper metabolism-related Genes in entorhinal cortex for Alzheimer's disease.Sci Rep. 2023 Oct 14;13(1):17458. doi: 10.1038/s41598-023-44656-9. Sci Rep. 2023. PMID: 37838728 Free PMC article.
-
Menopausal hormone therapy and risk of dementia: health insurance database in South Korea-based retrospective cohort study.Front Aging Neurosci. 2023 Sep 7;15:1213481. doi: 10.3389/fnagi.2023.1213481. eCollection 2023. Front Aging Neurosci. 2023. PMID: 37744387 Free PMC article.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical